Also Read: Sanofi’s Blood Cancer Drug’s New Subcutaneous Formulation Hits Primary Goal In Late-Stage In Multiple Myeloma The facility’s quality unit was also scrutinized for its inability to ...
Summarizing the manufacturing infractions, the FDA argued that Sanofi’s quality unit at the Framingham plant is unable to fully exercise its authority and responsibilities. Sanofi charts biggest ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback